| 1.1 All‐cause death |
6 |
1689 |
Risk Ratio (M‐H, Fixed, 95% CI) |
0.96 [0.65, 1.41] |
| 1.1.1 Cerebrolysin dose: 30 mL for 10 days |
3 |
1235 |
Risk Ratio (M‐H, Fixed, 95% CI) |
0.88 [0.56, 1.39] |
| 1.1.2 Cerebrolysin dose: 50 mL for 21 days |
1 |
146 |
Risk Ratio (M‐H, Fixed, 95% CI) |
0.87 [0.29, 2.58] |
| 1.1.3 Cerebrolysin dose: 10 mL and 50 mL for 10 days |
1 |
36 |
Risk Ratio (M‐H, Fixed, 95% CI) |
1.17 [0.37, 3.73] |
| 1.1.4 Cortexin dose: 20 mg for 10 days, 10 days rest, then 20 mg for 10 days |
1 |
168 |
Risk Ratio (M‐H, Fixed, 95% CI) |
2.17 [0.12, 39.28] |
| 1.1.5 Cortexin dose: 20 mg for 10 days, 10 days rest, then placebo for 10 days |
1 |
104 |
Risk Ratio (M‐H, Fixed, 95% CI) |
3.16 [0.17, 59.53] |
| 1.2 Non‐death attrition |
6 |
1689 |
Risk Ratio (M‐H, Random, 95% CI) |
0.72 [0.38, 1.39] |
| 1.2.1 Cerebrolysin dose: 30 mL for 10 days |
3 |
1235 |
Risk Ratio (M‐H, Random, 95% CI) |
0.87 [0.50, 1.52] |
| 1.2.2 Cerebrolysin dose: 50 mL for 21 days |
1 |
146 |
Risk Ratio (M‐H, Random, 95% CI) |
0.26 [0.08, 0.91] |
| 1.2.3 Cerebrolysin dose: 10 mL and 50 mL for 10 days |
1 |
36 |
Risk Ratio (M‐H, Random, 95% CI) |
Not estimable |
| 1.2.4 Cortexin dose: 20 mg for 10 days, 10 days rest, then 20 mg for 10 days |
1 |
168 |
Risk Ratio (M‐H, Random, 95% CI) |
Not estimable |
| 1.2.5 Cortexin dose: 20 mg for 10 days, 10 days rest, then placebo for 10 days |
1 |
104 |
Risk Ratio (M‐H, Random, 95% CI) |
Not estimable |
| 1.3 Total number of people with SAEs |
3 |
1335 |
Risk Ratio (M‐H, Fixed, 95% CI) |
1.16 [0.81, 1.66] |
| 1.3.1 Cerebrolysin dose: 30 mL for 10 days |
2 |
1189 |
Risk Ratio (M‐H, Fixed, 95% CI) |
1.23 [0.83, 1.81] |
| 1.3.2 Cerebrolysin dose: 50 mL for 21 days |
1 |
146 |
Risk Ratio (M‐H, Fixed, 95% CI) |
0.75 [0.26, 2.12] |
| 1.4 Total number of people with fatal SAEs |
3 |
1335 |
Risk Ratio (M‐H, Fixed, 95% CI) |
0.90 [0.59, 1.38] |
| 1.4.1 Cerebrolysin dose: 30 mL for 10 days |
2 |
1189 |
Risk Ratio (M‐H, Fixed, 95% CI) |
0.90 [0.57, 1.44] |
| 1.4.2 Cerebrolysin dose: 50 mL for 21 days |
1 |
146 |
Risk Ratio (M‐H, Fixed, 95% CI) |
0.87 [0.29, 2.58] |
| 1.5 Total number of people with non‐fatal SAEs |
3 |
1335 |
Risk Ratio (M‐H, Fixed, 95% CI) |
2.39 [1.10, 5.23] |
| 1.5.1 Cerebrolysin dose: 30 mL for 10 days |
2 |
1189 |
Risk Ratio (M‐H, Fixed, 95% CI) |
2.87 [1.24, 6.69] |
| 1.5.2 Cerebrolysin dose: 50 mL for 21 days |
1 |
146 |
Risk Ratio (M‐H, Fixed, 95% CI) |
0.29 [0.01, 7.03] |
| 1.6 Total number of people with adverse events |
4 |
1607 |
Risk Ratio (M‐H, Fixed, 95% CI) |
1.03 [0.92, 1.14] |
| 1.6.1 Cerebrolysin dose: 30 mL for 10 days |
2 |
1189 |
Risk Ratio (M‐H, Fixed, 95% CI) |
1.00 [0.90, 1.11] |
| 1.6.2 Cerebrolysin dose 50 mL for 21 days |
1 |
146 |
Risk Ratio (M‐H, Fixed, 95% CI) |
1.62 [0.69, 3.82] |
| 1.6.3 Cortexin dose: 20 mg for 10 days, 10 days rest, then 20 mg for 10 days |
1 |
168 |
Risk Ratio (M‐H, Fixed, 95% CI) |
1.57 [0.50, 4.96] |
| 1.6.4 Cortexin dose: 20 mg for 10 days, 10 days rest, then placebo for 10 days |
1 |
104 |
Risk Ratio (M‐H, Fixed, 95% CI) |
1.22 [0.42, 3.55] |
